October 22, 2012—The results of a matched-pair comparison of patients with metastatic colorectal cancer predominantly affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres (Sirtex Medical Limited, Sydney, Australia) significantly prolonged survival compared to best supportive care (BSC) alone. Ricarda Seidensticker, MD, et al published the study in Cardiovascular and Interventional Radiology (2012;35:1066–1073).
LAGUNA HILLS, Calif., Oct. 22, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year s Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami.
Circumferential ultrasound heating is potentially a more uniform and effective method for performing renal denervation than radiofrequency systems, Marc Sapoval, Department of Cardiovascular Radiology, European Hospital Georges Pompidou, Paris, France, told delegates at the CIRSE annual meeting (15–19 September, Lisbon, Portugal).
Sirtex Medical has announced the treatment of the first patients in Latin America with its SIR-Spheres microspheres used in the treatment of inoperable liver tumours. The first procedure took place on 10 October at the Hospital Italiano de Buenos Aires, Argentina, which is the first centre to offer the therapy in Latin America.
The US Food and Drug Administration has given 510(k) clearance to Surefire Medical for its line of Surefire Angiographic Catheters. Surefire Medical will launch these products in the United States later this year.
ALBANY, N.Y. and NORWELL, Mass., Oct. 8, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (ANGO), a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it has entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.
MINNEAPOLIS - October 3, 2012 - Medtronic, Inc. (NYSE: MDT) announced today that it has successfully completed the first phase of the feasibility study of its next-generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radio-frequency (RF) generator. A total of nine patients were treated with a 100 percent acute success rate in accessing the vessels and delivering therapy. The investigational next-generation Symplicity(TM) system is not commercially available anywhere in the world.
MINNEAPOLIS - October 3, 2012 - Medtronic, Inc. (NYSE: MDT) announced today that it has successfully completed the first phase of the feasibility study of its next-generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radio-frequency (RF) generator. A total of nine patients were treated with a 100 percent acute success rate in accessing the vessels and delivering therapy. The investigational next-generation Symplicity(TM) system is not commercially available anywhere in the world.
On 3 September, Medtronic announced that it has successfully completed the first phase of the feasibility study of its next generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radiofrequency (RF) generator.
A study published in the Journal of the American College of Cardiology, based on data from the Symplicity HTN-2 trial, suggests that renal denervation may be a cost-effective method of managing resistant hypertension and may result in a reduction in cardiovascular morbidity and mortality in the long term.
Electrophysiologist Clemens Jilek, German Heart Centre Munich, Germany, presented on how the technique of renal ablation could affect the renal artery and how renal denervation could be improved at CIRSE 2012 (15–19 September, Lisbon, Portugal) in a presentation titled “How bad is radiofrequency for the renal arteries?”
Key members of the Society of Interventional Radiology (SIR) have praised a new dual certificate for diagnostic radiology and interventional radiology, saying it recognises interventional radiology as a “a new form of medicine”.
At CIRSE 2012 (Lisbon, Portugal, 15–19 September), Philips and Biocompatibles announced a collaboration to advance the use of image guidance to control the delivery of beads during the arterial embolization of hypervascularised tumours.
The US Food and Drug Administration (FDA) has given 510(k) clearance to Access Scientific for its 4Fr Nanopuncture Powerwand.
On 11 September, the American Board of Medical Specialties (ABMS) recognised the unique interventional radiology skill set with the new dual certificate in interventional radiology and diagnostic radiology. The Society of Interventional Radiology (SIR) has hailed the affirmation of the specialty s role in patient care.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos